Amicus Therapeutics, a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has executed a definitive agreement for a $400 million credit facility...
view press release
July 17, 2020, 08:58 AM
|
Grovepoint Capital and Hayfin Capital Management have provided a €25m debt facility to German-based retailer NKD (“NKD or “the Company”). Grovepoint and Hayfin jointly led and structured the debt financing, and Grovepoint acts as facility agent and...
view press release
January 19, 2015, 07:16 AM
|